Jalpa Doshi, PhD

Jalpa Doshi, PhD
Senior Fellow

Division of General Internal Medicine, Perelman School of Medicine

Public Health Interests

Aging, Behavioral Economics, Chronic Medical Conditions, Drug Utilization, Law, Policy



Current Public-Health Related Activities

Jalpa A. Doshi, PhD, is Professor of Medicine at Penn's Perelman School of Medicine. She is also Director of Value Based Insurance Design Initiatives at the Center for Health Incentives and Behavioral Economics and Director of the Economic Evaluations Unit of the Center for Evidence-based Practice at Penn. The goal of her research program is to understand how pharmaceuticals can be better accessed and utilized in the health care system to improve health care quality while balancing costs. Her research focuses on three broad areas. First, it examines the impact of prescription benefit design and reimbursement policies on access to prescription drugs, and the quality and cost of health care. Second, her work focuses on the prevalence, causes, outcomes, and costs of suboptimal medication use in chronic diseases and the clinical and economic impact of innovative behavioral or policy interventions for improving medication adherence and management. Third, her research focuses on advancing the methods used in pharmaceutical outcomes and cost-effectiveness research to enhance its usefulness in real world decision-making by patients, providers, payers, and policymakers. In recent years, her research program in all three areas has focused on specialty drugs, which have become increasingly important treatment options for patients with serious, rare, and/or chronic diseases.

Select Publications:

Doshi JA, Puckett JT, Parmacek MS, Rader DJ.: "Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across U.S. Private and Public Payers." Circ Cardiovasc Qual Outcomes 2018 Notes: doi: 10.1161/CIRCOUTCOMES.117.003939. Accompanying editorial.

Li P, Wong YN, Jahnke J, Doshi JA: "Association of High Cost Sharing and Target Therapy Initiation among Medicare Patients with Metastatic Renal Cell Carcinoma." Cancer Medicine 7(1): 75-86, 2018 Notes: DOI: 10.1002/cam4.1262.

Doshi JA, Li P, Pettit AR, Dougherty JS, Flint A, Ladage VP: "Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of 'Too Much Too Soon'." American Journal of Managed Care 23(3 Suppl): S39-S45, 2017.

Doshi JA, Li P, Desai S, Marcus S : "Impact of Medicaid Prescription Copayments on Use of Antipsychotics and Other Medications in Patients with Schizophrenia." Journal of Medical Economics 20(12): 1252-1260, 2017 Notes: doi: 10.1080/13696998.2017.1365720. [Epub ahead of print]